Prior anticancer treatment within  days (or  times the half-life time, whichever is shorter) or any investigational agent within  days prior to the first dose of study drugs. All acute toxicities related to prior treatments must be resolved to Grade less than or equal to 
Patients who have received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational agents within  days or five half-lives, whichever is greater (with exception of hydroxyurea), prior to drug administration on this study.
The subject should be off any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational agents for at least  days or  half lives, whichever is greater, prior to enrollment with the exception of hydroxyurea. All prior treatment-related non-hematologic toxicities must have resolved to ? grade  prior to screening.
anti-cancer treatments (including cytotoxic chemotherapy, radiotherapy, hormonal therapy, biologic, immunotherapy or investigational drugs) received within  days or  half-lives for targeted therapies (whichever is shorter) before first dose of study drug (to be supplemented)
Concurrent anticancer treatment, major surgery or use of any investigational drug within  days or  half-lives, whichever is shorter, before the start of trial treatment; palliative radiation therapy is allowed if >  days before planned first dose of study drugs and any toxicity is ? Grade .
Prior systemic standard or investigational anticancer therapy, including target therapy, chemotherapy, immunotherapy within  days prior to the first dose of study drug. The above mentioned conditions which the Investigator considers there is no more drug effect, such as ? half-lives are permitted
Any small molecule, biologic, or hormonal agent within  days or a washout period equal to  half-lives (whichever is shorter). At least  days must have elapsed between the last dose of such agent and the first dose of study drug.
Treated with at least one line of chemotherapy in the palliative setting or with neoadjuvant or adjuvant chemotherapy within the prior six months; the allowable window between treatments is  days for chemotherapy or a tyrosine kinase inhibitor (TKI) or  half-lives for a TKI (whichever is shorter),  days and progression by CT for immunotherapy,  days for RT,  days for surgery, or  days for an investigational agent
Treatment with any systemic anticancer treatment (including investigational products) within  days or  half-lives, whichever is shorter, before the first dose of study drug.
Prior antitumor therapy as follows, before the first dose of study drug: Targeted therapy, epigenetic therapy, or treatment with an investigational drug or used an invasive investigational medical device within  days or at least  half-lives, whichever is less; Monoclonal antibody treatment for multiple myeloma within  days; Cytotoxic therapy within  days; Proteasome inhibitor therapy within  days; Immunomodulatory agent therapy within  days; Radiotherapy within  days. However, if the radiation portal covered less than or equal to (<=) % of the bone marrow reserve, the participant is eligible irrespective of the end date of radiotherapy
At least  weeks or  half-lives, whichever is shorter, since receiving systemic anticancer therapy, including investigational agents. At least  weeks since receiving radiation therapy
Received any of the following prior anticancer therapy:\r\n* Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy (RIT), or intra-operative radiotherapy (IORT); Note: stereotactic radiosurgery (SRS) is allowed\r\n* Non-antiangiogenic therapy (including investigational agents and small molecular kinase inhibitors) within  days or  half-lives, whichever is shorter, prior to the first dose of study drug\r\n* Biologic agents (antibodies, immune modulators, vaccines, cytokines) within  days prior to first dose of study drug\r\n* Nitrosoureas or mitomycin C within  days or metronomic/protracted low- dose chemotherapy within  days, or other cytotoxic chemotherapy within  days, prior to first dose of study drug\r\n* Prior treatment with TVB-\r\n* Prior treatment with Carmustine Wafers
Any systemic therapy, including monoclonal antibody within  days or  half-lives (whichever is shorter) of initiating protocol therapy
Investigational therapy, chemotherapy, immunotherapy, radiotherapy, or systemic graft versus host disease (GVHD) therapy within two weeks or five half-lives (whichever is shorter); steroids, hydroxyurea and/or leukapheresis are allowed to control blast count prior to the first dose of study drug
Patients who have received prior systemic therapy <  days prior to study registration or have not recovered adequately from toxicities to CTCAE v. . grade  or less; prior investigational therapy may not have been given <  half-lives of last dose of treatment, or <  days, whichever is greater
Subject has received anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within a period of  days or  half-lives (whichever is shorter) prior to study day 
The subject has received any of the following prior anticancer therapy:\r\n* Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy, or intra-operative radiotherapy (IORT) to the target site\r\n* Radiation therapy within  weeks of screening\r\n* Systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (e.g., tamoxifen) within  days or  half-lives, whichever is shorter, prior first dose of study drug\r\n* Biologic agents (antibodies, immune modulators, vaccines, and cytokines) within  days prior to first dose of study drug\r\n* Nitrosoureas or mitomycin C within  days, or metronomic/protracted low-dose chemotherapy within  days, or other cytotoxic chemotherapy within  days, prior to first dose of study drug\r\n* Prior treatment with carmustine wafers\r\n* Patients who are currently receiving any other investigational agents and/or who have received an investigational agent in the prior  days
Any systemic therapy, including monoclonal antibody within  days or  half-lives (whichever is shorter) of initiating protocol therapy
Treated with systemic anticancer therapy or an investigational agent within  weeks or  half-lives, whichever is shorter, prior to start of study drug treatment. Washout will be  weeks for antibody therapy and immunotherapy.
Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment; receipt of any investigational or approved anticancer therapy (chemotherapy, targeted therapy, biologic therapy, monoclonal antibodies, etc.) within  days or  half lives, whichever is shorter, prior to the first dose of MEDI; concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
Any systemic therapy, including monoclonal antibody within  days or  half-lives (whichever is shorter) of initiating day  of protocol therapy
Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within  days or  half-lives (whichever is shorter) prior to first dose of study drug; hydroxyurea is permitted up to the day before initiation of study treatment
Subject has received any anti-cancer therapy including chemotherapy, immunotherapy, biologic, targeted therapy, or any investigational therapy within either  days or  half-lives (whichever is shorter), prior to study drug administration
Prior EGFR inhibitor within  days; received prior treatment with any other agent with antitumor activity chemotherapy, radiotherapy, or immunotherapy within  days; any investigational therapy within  days or  half-lives, whichever is shorter; blood transfusion or hemopoietic factor within  days; major surgery within  days; any strong CYPA inhibitors within  days
Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
Any concurrent anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational agents (with the exception of hydroxyurea or leukapheresis for control of hyperleukocytosis) within  days or five half-lives of drugs, whichever is shorter, prior to Cycle  Day 
Patients currently receiving anticancer therapies (including chemotherapy, radiation therapy, hormonal, or antibody-based therapy); prior treatment should have a washout period of  days or  / half-lives ( days), whichever is shorter
Receipt of any investigational anticancer therapy within  days or  half-lives, whichever is shorter, prior to the first dose of study treatment.
The subject has received any of the following prior anticancer therapy:\r\n* Non-standard radiation therapy such as brachytherapy, systemic radioisotope therapy, or intra-operative radiotherapy (IORT); Note: stereotactic radiosurgery (SRS) is allowed\r\n* Non-bevacizumab systemic therapy (including investigational agents and small-molecule kinase inhibitors) or non-cytotoxic hormonal therapy (eg, tamoxifen) within  days or  half-lives, whichever is shorter, prior first dose of study drug\r\n* Biologic agents (antibodies, immune modulators, vaccines, cytokines) within  days prior to first dose of study drug, with the exception of bevacizumab which can be  days or maintain the subject's current bevacizumab dosing schedule\r\n* Nitrosoureas or mitomycin C within  days, or metronomic/protracted low-dose chemotherapy within  days, or other cytotoxic chemotherapy within  days, prior to first dose of study drug\r\n* Prior treatment with carmustine wafers\r\n* Prior treatment with TH-
Treatment with other anticancer drugs within  days or  half-lives of anticancer therapy (whichever is shorter) is prohibited from  days prior to the first dose of SNX- and throughout the study.
Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within  days or  half-lives (whichever is shorter) prior to first dose of study drug.
Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within  days or  drug half-lives (if drug half-life in patients is known), whichever is shorter (or within  weeks for mitomycin C) before start of the study treatment
Previous investigational drug or any anticancer therapy in the  days (or  half-lives for non-cytotoxics, whichever is shorter) prior to the start of trial treatment
Any anticancer therapy including; small molecules, immunotherapy, chemotherapy monoclonal antibodies or any other experimental drug within four weeks or five half lives, whichever is longest, before first infusion.
Systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any experimental therapy within  days or  half-lives, whichever is shorter, before the first dose of either study drug
Treatment with other anticancer drugs within  days or  half-lives of anticancer therapy (whichever is shorter), and treatment with any other investigational agent is prohibited from  days prior to the first dose of SNX- and throughout the study.
Anticancer therapy including blinatumomab or chemotherapy, radiation therapy, targeted small molecule agents, investigational agents within  days or  half-lives, whichever is shorter
Prior treatment with the following therapies:  Anticancer therapy within  days or  half-lives of the drug, whichever is shorter. At least  days must have elapsed between the last dose of prior anticancer agent and the first dose of study drug is administered.  Part B (GSK/pembrolizumab combination): prior pembrolizumab washout is not required.  Prior radiation therapy: permissible if at least one non-irradiated measurable lesion is available for assessment according to RECIST version . or if a solitary measurable lesion was irradiated, objective progression is documented. A wash out of at least two weeks before start of study drug for radiation of any intended use to the extremities for bone metastases and  weeks for radiation to the chest, brain, or visceral organs is required.  Investigational therapy within  days or  half-lives of the investigational product (whichever is shorter). At least  days must have elapsed between the last dose of investigational agent and the first dose of study drug is administered.
Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any investigational therapy within  days or  half-lives (whichever is shorter) prior to first dose of study drug
Treatment with anticancer therapy or investigational drug or device within  wk ( wk for nitrosureas or mitomycin C) or  half-lives of agent, whichever is shorter, prior to first drug dose, and any drug-related toxicities must have recovered to grade  or less
Prior treatment with investigational agents =< days or =<*their half-lives (whichever is shorter) before the first dose of study treatment. A minimum of  days should elapse from prior therapy to initiating protocol therapy.